Altimmune, Inc.(ALT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,937 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in ALT
Events flagged as statistical outliers against ALT's own multi-year baseline — not fixed dollar thresholds.
ALT Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Altimmune, Inc. (ALT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALT at 8.0/100 on a 32-signal composite quality model, placing it at rank #2,937 of 2,962 stocks — the bottom half of the AI-ranked universe. ALT scores in the top quartile across institutional flow (99.1). Areas of concern include profitability (0.1) and free cash flow (0.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Altimmune, Inc. reports net income of $-22.8M, free cash flow of $-24.3M. Top institutional holders of ALT by reported 13-F value include BlackRock, Deep Track Capital, STATE STREET, based on the most recent SEC filings. ALT trades on the Nasdaq exchange and files with the SEC under CIK 1326190. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Altimmune, Inc. directly from SEC EDGAR. Altimmune, Inc.'s 13F Pro composite quality score has ranged between 2 and 28 since 2021, currently 8.0 — an improving long-term trajectory across 64 quarterly and live scoring snapshots.
Net Income
Q2 2026
$-22.8M
Free Cash Flow
Q2 2026
$-24.3M
ROIC
Q2 2026
-20.6%
D/E Ratio
Q2 2026
0.07
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+105.0% YoYNet Income
+7.3% YoYOperating Income
+8.4% YoYEPS (Diluted)
+25.4% YoYTotal Assets
+100.9% YoYTotal Debt
Op. Cash Flow
+15.4% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $41.0K +105.0% | $20.0K -95.3% | $426.0K +726.5% | $-68.0K -101.5% | $4.4M -46.1% | $8.2M |
| Net Income | $-88.1M +7.3% | $-95.1M -7.5% | $-88.4M -4.4% | $-84.7M +12.7% | $-97.1M -98.0% | $-49.0M |
| Operating Income | $-94.5M +8.4% | $-103.2M -7.6% | $-95.9M -9.3% | $-87.7M +9.5% | $-96.9M -76.9% | $-54.8M |
| EPS (Diluted) | $-1.00 +25.4% | $-1.34 +19.3% | $-1.66 +8.3% | $-1.81 +23.0% | $-2.35 -23.0% | $-1.91 |
| Total Assets | $279.9M +100.9% | $139.3M -33.9% | $210.6M +1.8% | $206.9M -5.5% | $218.9M -10.7% | $245.1M |
| Total Debt | $34.3M | — | — | $4.6M +215.1% | $1.5M -20.5% | $1.8M |
| Operating Cash Flow | $-67.5M +15.4% | $-79.8M -5.3% | $-75.8M -21.1% | $-62.6M +20.0% | $-78.2M -128.1% | $-34.3M |
| Free Cash Flow | $-67.5M | — | $-75.9M -21.0% | $-62.7M +30.6% | $-90.4M -161.8% | $-34.5M |
Get alerted when ALT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Altimmune, Inc. including:
Top Institutional Holders of ALT
BlackRock, Inc.
$62.0M20,385,284 shDeep Track Capital, LP
$58.5M19,250,000 shSTATE STREET CORP
$36.8M12,098,540 shTCG Crossover Management, LLC
$30.4M10,000,000 shVANGUARD CAPITAL MANAGEMENT LLC
$24.9M8,177,752 shVANGUARD PORTFOLIO MANAGEMENT LLC
$22.3M7,330,265 shMARSHALL WACE, LLP
$20.8M6,841,055 shVIKING GLOBAL INVESTORS LP
$20.4M6,700,000 shRA CAPITAL MANAGEMENT, L.P.
$19.8M6,500,000 shGEODE CAPITAL MANAGEMENT, LLC
$15.2M5,011,314 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $62.0M | 20,385,284 |
| Deep Track Capital, LP | $58.5M | 19,250,000 |
| STATE STREET CORP | $36.8M | 12,098,540 |
| TCG Crossover Management, LLC | $30.4M | 10,000,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $24.9M | 8,177,752 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $22.3M | 7,330,265 |
| MARSHALL WACE, LLP | $20.8M | 6,841,055 |
| VIKING GLOBAL INVESTORS LP | $20.4M | 6,700,000 |
| RA CAPITAL MANAGEMENT, L.P. | $19.8M | 6,500,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $15.2M | 5,011,314 |
Companies Similar to ALT
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
4D Molecular Therapeutics, Inc.
Editas Medicine, Inc.
Century Therapeutics, Inc.
PROKIDNEY CORP.
Janux Therapeutics, Inc.
LENZ Therapeutics, Inc.
Zai Lab Ltd
Inhibrx Biosciences, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ALT on your watchlist
Track score changes the day Altimmune, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ALT a good stock to buy?
13F Pro's AI-powered analysis of Altimmune, Inc. (ALT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALT are available on the ALT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ALT is classified as a small company.
Which hedge funds own ALT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Altimmune, Inc.'s investment landscape.